We studied the guidelines on the serum bilirubin concentration of 12mg% for the management of neonatal jaundice and compared the effectiveness of oral phenobarbital and continuous phototherapy with singularly phototherapy, in reducing neonatal hyperbilirubinemia in the 100 cases admitted to the department of pediatrics, St. Benedict Hospital from April 1977 to August 1977. The results were as follows; 1. Among the 35 full term normal newborn infants without any risk factors for kernicterus, 14 infants had serum bilirubin concentration below 12mg%. In this group, 5 infants received phototherapy (35.7%). 21 infants had serum bilirubin concentration above 12mg%. In the latter group, 5 infants received phototherapy (71.4%) 2. The mean rate of fall of serum bilirubin per day was 1.81mg% in phototherapy plus phenobarbital groups and 1.57mg% in singularly phototherapy. 3. The mean peak rate of fall of serum bilirubin was 2.28mg% per day in the third to fourth day of phototherapy and phenobarbital groups and 2.76mg% per day in the fourth to fifth day of singularly phototherapy. 4. The mean duration of phototherapy was 74 hours in phototherapy plus phenobarbital groups and 82 hours in singularly phototherapy.
Bilirubin* ; Humans ; Hyperbilirubinemia, Neonatal ; Infant ; Infant, Newborn ; Jaundice, Neonatal* ; Kernicterus ; Pediatrics ; Phenobarbital* ; Phototherapy* ; Risk Factors

The most devastating clinical consequence of G-6-PD deficiency is neonatal hyperbilirubinemia which can be severe and result in kernicterus or even death, although glucose-6-phosphate dehydrogenase deficiency is responsible for two clinical syndromes, an episodic hemolytic anemia induced by infections or certain drugs and spontaneous chronic nonspherocytic hemolytic anemia. In the pathogenesis of neonatal hyperbilirubinemia associated with G-6-PD deficiency, decreased elimination of bilirubin has been suspected to be a key factor, because these neonates usually do not develop frank anemia even in the presence of severe hyperbilirubinemia. But, we experienced a glucose-6-phosphate dehydrogenase deficient male patient who showed jaundice and severe hemolytic anemia appearing within the first 24 hour of life. The patient had resolution of symptoms after phototherapy and transfusion. We report this case with a brief review of the related literatures.
Anemia ; Anemia, Hemolytic* ; Bilirubin ; Glucose-6-Phosphate* ; Glucosephosphate Dehydrogenase Deficiency* ; Glucosephosphate Dehydrogenase* ; Humans ; Hyperbilirubinemia ; Hyperbilirubinemia, Neonatal ; Infant, Newborn ; Jaundice* ; Kernicterus ; Male ; Phototherapy

No abstract available.
Hyperbilirubinemia, Neonatal*

No abstract available.
Hyperbilirubinemia, Neonatal*

No abstract available.
Hyperbilirubinemia, Neonatal*

No abstract available.
Hyperbilirubinemia, Neonatal*

Clinical and statistical observations were performed on 97 newborn infants who were admitted to newborn nursery of St. Paul's Hospital from September, 1978 to August, 1979 with the diagnosis of idiopathic neontal hyperbilirubinemia and the following results were obtained. 1. The highest monthly incidence was seen in March with 19 cases(19.2%). 2. The peak gestational age and birth weight were 40 weeks(33.0%) and 3,001-3,500 gm(38.2%), respectively. 3. In majority of cases appearence of jaundice was seen between 2 and 4 days. The peak value was reached between 3 and 8 days in premature infants and between 3 and 5 days in term infants. 4. The peak serum bilirubin levels in most of premature infants were 12.1-16.0mg% and term infants were 14.1-18.0mg%. 5. Apgar score at 1 minute and 5 minutes in majority of newborn infants were 7-10. 6. Total number o cases who were received exchange transfusion were 5 (5.2%).
Apgar Score ; Bilirubin ; Birth Weight ; Diagnosis ; Gestational Age ; Humans ; Hyperbilirubinemia ; Hyperbilirubinemia, Neonatal* ; Incidence ; Infant ; Infant, Newborn ; Infant, Premature ; Jaundice ; Nurseries

A clinical and hematological observation was performed on 136 newborn infants who were admitted to dept. of Pediatrics of Chosun University Hospital from Junly, 1976 to June, 1980 and were diagnosed of neonatal hyperbilirubinemia. The following results were obtained 1) The incidence of hyperbilirubinemia in male (64.0%) was more than female. 2) The highest monthly incidence was seen in June with 23 cases. (16.9%) 3) In the observation of the gestational period, its incidence was highest in full-term neonate with 103 cases. (79.3%). The mean value of serum bilirubin was highest in postmature neonate (19.70mg%). 4) In the obseervatio of the delivery type, the mean value of serum bilirubin was highest in vacuum and forcep delivery (17.81mg%). 5) The mean value of serum bilirubin was more higher in those of low birth weight group. 6) In the distribution of peak value of serum bilirubin, a group of 10.1~20.0mg% occupied 75.7%. 7) Idiopathic hyperbilirubinemia was the most common cause of pathological hyper bilirubinemia, with 79 cases. (58.1%). In the group of blood incompathibily, visible jaundice was begun earliest and mean value of serum bilirubin was highest. 8) Sepsis among the infection was the most important factor in the cause of neonatal hyper bilirubinemia with 18 cases (51.4%). 9) The most common blood types of mother-baby in ABO blood incompatibility was O-B with 8 cases (61.5%). 10) The exchange transfusions were performed on 13 cases (9.5%) and the rate of performance was the highest in blood incompatibility.
Bilirubin ; Female ; Humans ; Hyperbilirubinemia ; Hyperbilirubinemia, Neonatal ; Incidence ; Infant, Low Birth Weight ; Infant, Newborn ; Jaundice* ; Male ; Pediatrics ; Sepsis ; Surgical Instruments ; Vacuum

PURPOSE: Cholestylamine has been shown to release chloride ion and absorbs bile acid in the intestine, forming a nonabsorbable complex preventing enterohepatic circulation. The purpose of this study is to clarify the value of cholestylamine and the adequate dosage, in combination with phototherapy, as well as to confirm whether it shorten the duration of hospitalization. METHODS: Total 80 full-term neonates with a total bilirubin level greater than 12mg/dL were studied. The neonates were randomly divided into four groups : (1) Only phototherapy group (A)(2) 250mg/kg/day cholestylamine with phototherapy group (B)(3) 500mg/kg/day cholestylamine with phototherapy group (C)(4) 1000mg/kg/day cholestylamine with phototherapy group (D). RESULTS: Forty-eight hours, 72 hours and 96 hours after the beginning of the study, the mean bilirubin level among the B, C, D groups significantly diminished than A group (P<0.05). The duration of phototherapy and hospitalization significantly diminished in the D group. After phototherapy, finished mean bilirubin level was markedly diminished in the D group. CONCLUSION: The data revealed that oral administration of cholestylamine (especially 1000mg/kg/ day cholestylamine with phototherapy group : D) not only increased the efficacy of phototherapy, but also shortened the duration of phototherapy.
Administration, Oral* ; Bile ; Bilirubin ; Enterohepatic Circulation ; Hospitalization ; Humans ; Hyperbilirubinemia, Neonatal* ; Infant, Newborn ; Intestines ; Jaundice, Neonatal ; Phototherapy*

PURPOSE: TATA box mutation/polymorphism in the promoter region of the bilirubin uridinediphosphoglucuronate glucuronosyltransferase 1A1 (UGT-1A1) gene is known to be an etiology of hyperbilirubinemia. This study examined if a TATA box mutation/polymorphism in UGT-1A1 gene promoter could be associated with the development of severe early neonatal jaundice in Korean infants. METHODS: Thirty-nine neonatal jaundice patients and 40 controlled infants were analyzed for UGT-1A1 promoter genotypes by using DNA sequencing. RESULTS: The homozygote for (TA)7TAA mutation was not found in this study. Comparison of the prevalence of UGT-1A1 promoter (TA)7TAA heterozygotes revealed no difference between the group with jaundice and the controlled group (15.4% vs. 10%). The peak bilirubin level was higher and the onset of jaundice was earlier in the jaundice group with (TA)7TAA heterozygote compared to the jaundice group without (TA)7TAA heterozygote (23.2+/-1.0 mg/dL vs. 19.7+/-2.4 mg/dL, P=0.004, 5.0+/-1.5 days vs. 8.3+/-4.1 days, P= 0.057). CONCLUSION: The results of this study showed that TATA box polymorphism in UGT-1A1 gene promoter did not increase the prevalence of severe early neonatal jaundice in Korean infants.
Bilirubin ; Genotype ; Glucuronosyltransferase ; Heterozygote ; Homozygote ; Humans ; Hyperbilirubinemia ; Hyperbilirubinemia, Neonatal* ; Infant ; Infant, Newborn ; Jaundice ; Jaundice, Neonatal ; Prevalence ; Promoter Regions, Genetic ; Sequence Analysis, DNA ; TATA Box